Mitchell Steiner

“So Viru is a late-stage clinical pharmaceutical company, and we had done a hard pivot back in October of 2023 to focus on GLP-1 muscle wasting that occurs, the loss of muscle, and our drug, Enobus Arm, is a drug that came from a previous company I had called GTX, and it's been through six studies in muscle, and so we…”

“With me on this morning's call is Dr. Gary Barnett, our Chief Scientific Officer, Michelle Greco, Chief Financial Officer and Chief Administrative Officer, Phil Greenberg, our General Counsel, and Sam Fish, Executive Director of Investor Relations and Corporate Communications.”

“With me on this morning's call are Dr. Gary Barnett, the Chief Scientific Officer, Michelle Greco, the Chief Financial Officer and Chief Administrative Officer, Phil Greenberg, General Counsel, and Sam Fish, the Executive Director of Investor Relations and Corporate Communications.”

“First of all, we're making forward-looking statements. I refer you to the risks that are summarized in our 10K and recent 10Q. you. Viru had done a hard pivot, taking one of our exciting drugs, the Novus Arm, and putting it together with the GLP-1.”

“The statements made on this conference call may be forward-looking statements.”